Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
NCT ID: NCT06392763
Last Updated: 2024-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
602 participants
OBSERVATIONAL
2021-08-03
2023-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
NCT06765876
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
NCT06064903
An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
NCT06721598
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
NCT05349201
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT02535364
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KYMRIAH DLBCL
No interventions assigned to this group
YESCARTA DLBCL
No interventions assigned to this group
CAR-T DLBCL
No interventions assigned to this group
KYMRIAH ALL
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND
* Diagnosed with DLBCL (International Classification of Diseases \[ICD-10 C833\]) when receiving CAR-T AND
* Being 18 years of age or older.
ALL population:
* Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND
* Diagnosed with ALL (ICD-10 C910) when receiving CAR-T AND
* Being 25 years of age or younger.
Exclusion Criteria
• Patients hospitalised with a diagnosis other than DLBCL during the historical period or during the index stay.
ALL population:
• Patients hospitalised with a diagnosis other than ALL during the historical period or during the index stay.
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis
Rueil-Malmaison, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCTL019A0FR03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.